Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peceleganan (PL-5) is a novel, chemically synthesized α-helical antimicrobial peptide (AMP) containing 26 amino acid residues. It is developed as a topical spray for the treatment of skin wound infections. Peceleganan acts as a cell membrane modulator, disrupting bacterial membranes and exhibiting broad-spectrum antibacterial activity against both gram-positive and gram-negative bacteria, including drug-resistant strains. Clinical trials have demonstrated that peceleganan spray is safe and has higher clinical efficacy than silver sulfadiazine in treating skin wound infections, though its bacterial clearance rate may be lower. The drug was independently developed by Jiangsu ProteLight Pharmaceutical and Biotechnology[1][2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on peceleganan.